{"nctId":"NCT00159822","briefTitle":"Voriconazole For Chronic Bronchopulmonary Aspergillosis","startDateStruct":{"date":"2005-07"},"conditions":["Aspergillosis"],"count":48,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Voriconazole"]}],"interventions":[{"name":"Voriconazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with a chronic bronchopulmonary aspergillosis assessed by a compatible chest imagery (CT scan) and/or an endoscopic lesion sourced by photo, would it be:\n* Complex aspergilloma non primarily operable,\n* Chronic necrotizing pulmonary aspergillosis,\n* Tracheo-bronchial aspergillosis, obstructive or necrotizing/pseudo-membranous.\n\nExclusion Criteria:\n\n* Patient with risk factor(s) of cardiac arrhythmia, symptomatic arrhythmia, treated by medication known to prolong QT interval, or prolongation of QTc interval \\> 450 msec in men and \\> 470 msec in women.\n* Simple aspergilloma with primary indication of surgical treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis","description":"Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50 percent on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Successful Global Outcome at Month 3 and End of Treatment: Chronic Bronchopulmonary Aspergillosis","description":"Successful global outcome: composite assessment of radiological and mycological responses; defined as complete (resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline) or partial (reduction in diameter ≥ 50 percent on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion) radiological response and mycological eradication after 3 months of treatment and after 9 or 12 months (in case of extension of treatment period beyond 6 months); no success=criteria not met. Assessment determined by DRC.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Successful Global Outcome at 6 Months: Chronic Necrotizing Pulmonary Aspergillosis (CNPA) and Tracheo-bronchial Aspergillosis","description":"Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Successful Global Outcome at 6 Months: Complex Aspergilloma","description":"Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Respiratory Clinical Signs and Symptoms on Visual Analog Scales (VAS)","description":"Subject assessment of improvement of respiratory clinical signs and symptoms as indicated by the subject placing a mark on a 10 cm VAS scored 0 (better state of health) to 100 (poor state of health) for cough, dyspnea, sputum, hemoptysis, chest tightness, and nocturnal awakening. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.80","spread":"33.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.63","spread":"35.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.45","spread":"43.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.13","spread":"37.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.65","spread":"41.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.67","spread":"24.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.22","spread":"25.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.40","spread":"24.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.69","spread":"25.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"31.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.03","spread":"27.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.86","spread":"37.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.62","spread":"37.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.47","spread":"26.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.67","spread":"36.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.13","spread":"28.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.11","spread":"27.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.52","spread":"30.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.31","spread":"31.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"20.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"37.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"29.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.52","spread":"33.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.29","spread":"31.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.00","spread":"22.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"29.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.86","spread":"36.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.40","spread":"31.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","spread":"31.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.29","spread":"41.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.67","spread":"18.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.99","spread":"20.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.16","spread":"24.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.87","spread":"20.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.58","spread":"20.43"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Relapse","description":"Relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \\[TDM\\] and or endoscopy) and mycologically (histology and or culture and or serology).","paramType":"NUMBER","dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Time to Relapse After EOT","description":"Time (months) to relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \\[TDM\\] and or endoscopy) and mycologically (histology and or culture and or serology).","paramType":"NUMBER","dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Global Survival: Number of Subjects With an Outcome of Death","description":"Number of subjects with an outcome of death (adverse event with a fatal outcome) through end of study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life (QOL): St. George's Hospital Respiratory Questionnaire","description":"Subject administered questionnaire to measure improvement in QOL; 50 questions exploring 3 different areas: symptoms, impact on activity profile (activity), and impact on daily life (impacts). Each item in an area is weighted based on empirical data; scores range from lowest possible weight 0 to highest possible weight 100. Scores for each section and total score calculated using score calculation algorithms with higher scores indicating poor health. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.50","spread":"22.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.32","spread":"7.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"29.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.72","spread":"23.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.84","spread":"23.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.15","spread":"17.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.43","spread":"17.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"18.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Complete or Partial Radiological Response","description":"Radiological response: based on chest TDM except for tracheo-bronchialaspergillosis which was assessed by bronchoscopy. Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Mycological Response of Eradication","description":"Mycological response: eradication: absence of aspergillus species (spp) in bronchopulmonary samples: sputum, bronchial aspirate or bronchoalveolar lavage (BAL) (negative direct examination \\[exam\\] and negative culture), and negative histological exam when available; persistence (no eradication): presence of aspergillus spp in any relevant bronchopulmonary samples. Not done (presumed eradication): case reviewed by DRC for any mycological exams not performed to assess if case should constitute presumed eradication (no sputum due to clinical improvement).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Complete or Partial Serological Response","description":"Serological response: normalization (complete response) defined as return to normal values (≤ 1 arc); partial response defined as significant decrease but not complete (decrease of 2 or more arcs compared to baseline). Complete or partial response summarized as Improvement; based on arc values at visit compared to arc values at baseline (inclusion).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":48},"commonTop":["Visual impairment","Bronchitis","Haemoptysis","Vision blurred","Insomnia"]}}}